Save on Yervoy with the RxLess Assurance Plan.
What is yervoy?
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older. (1.1) • Treatment of adult patients with unresectable or metastatic melanoma, in combination with nivolumab. (1.1) • Adjuvant treatment of patients with cutaneous melanoma with pathologic involv...ement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1.4) Hepatocellular Carcinoma • Treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab. (1.8) 1.1 Unresectable or Metastatic Melanoma YERVOY is indicated for the treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older. YERVOY, in combination with nivolumab, is indicated for the treatment of unresectable or metastatic melanoma in adult patients. 1.2 Adjuvant Treatment of Melanoma YERVOY is indicated for the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. 1.3 Advanced Renal Cell Carcinoma YERVOY, in combination with nivolumab, is indicated for the first-line treatment of patients with intermediate or poor risk advanced renal cell carcinoma (RCC). 1.4 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer YERVOY, in combination with nivolumab, is indicated for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.4) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.5 Hepatocellular Carcinoma YERVOY, in combination with nivolumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.5) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 1.6 Metastatic Non-Small Cell Lung Cancer YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test [see Dosage and Administration (2.1) ] , with no EGFR or ALK genomic tumor aberrations. YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations. 1.7 Malignant Pleural Mesothelioma YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. 1.8 Esophageal Cancer YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Read More
Once you download the RxLess mobile app, you become a member of the RxLess Assurance plan and will pay the lowest possible price for your yervoy medication. Review the discount offers and pharmacy prices below. Then, select the offer you want and present it to the pharmacist when you fill your prescription to get that price. That's it! There is nothing more to do or pay. Learn more about how the RxLess Assurance Plan works, or visit our FAQ page if you have questions. If you experience ANY issues at the pharmacy, please call us at 1-844-479-5377 for prompt assistance.
Generic: Brand:
More ways to save on yervoy
Fill a 90-Day Supply to Save
In some cases, filling your prescription for a 90-day supply will give you a lower total cost compared to filling the same prescription multiple times for smaller amounts. Even if the drug and the dosage are the same, you will need a brand new prescription from your doctor to switch to 90-day fills.
Your pharmacy cannot transfer a prescription for a 30-day supply into one with a 90-day supply. Also, some insurance plans may require that you use a mail order pharmacy for prescriptions greater than a 30-day supply.
Patient Assistance Programs
Many programs are available from government organizations, non-profits, and drug manufacturers to assist with the costs of medications. It’s free to sign up for these programs if you meet their requirements for eligibility. The enrollment options are different for each program, but they can usually be completed on- line, over the phone, or with the help of your doctor’s office.
Please note, patient assistance programs cannot be used in conjunction with these RxLess offers. Many times however, the offers listed on RxLess will be less expensive than manufacturer coupons, copay cards, or patient assistance programs – so make sure you compare all options before making a purchase.
Research Lower Cost Alternatives
There may be other prescriptions that work equally well at treating a condition, but that are available at different prices. Ask your doctor if there are any lower cost alternative drugs that - and if switching to a different drug could affect your treatment. To get started, check the section below for other drugs related to yervoy.
Save on yervoy Medication
Antineoplastic - Monoclonal Antibodies - Drugs that prevent or inhibit the maturation and proliferation of neoplasms, also known as anticancer drugs.